Extra chemo after eye removal for high-risk retinoblastoma
Part of Cancer, Eyes & vision clinical trials.
This Phase 3 study tests whether giving chemotherapy after the eye has been removed can lower the chance of retinoblastoma coming back for children with high-risk disease. You may be screened if your child had one eye affected and meet the staging and treatment history requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can sign consent and follow all study visits and tests during the whole study
- Pathology reports confirm retinoblastoma, Stage I (as defined by a standard staging system)
- Your child had the affected eye removed (enucleation) before starting the study
- The cancer is only in one eye (monocular retinoblastoma)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether a combination chemotherapy treatment (topotecan plus melphalan) can help children with retinoblastoma while keeping the eye when possible. It’s a Phase 3 study, meaning it’s testing effectiveness in a larger group of patients.
This trial studies whether newer “save-the-eye” treatment plans can control retinoblastoma (eye cancer) while keeping vision as good as possible. It compares different conservative treatment strategies depending on how the tumor looks and where it is.
This trial tests a high dose of a chemotherapy drug called topotecan given directly into the eye (intravitreal injection) for children with retinoblastoma that has come back or not responded to treatment and has seeds floating in the vitreous. The goal is to save the eye when removal is the only other option.
This trial looks at care recommendations for children with retinoblastoma (a childhood eye cancer). It may help standardize the best treatment approach for different patterns of tumor spread.
This trial tests a new way to deliver the chemotherapy drug topotecan directly to the eye (via a small patch placed on the eye surface) for children with retinoblastoma that either needs eye removal or has come back after standard treatment. It aims to see if this approach can help save the eye and vision.
This study looks at patients who have received additional cancer treatment after their initial retinoblastoma (eye cancer) therapy and tracks their recovery for at least one year. The research aims to understand how well this follow-up treatment works and what happens to patients over time.
Hear when a new Retinoblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.